| Literature DB >> 3516264 |
Abstract
Interferons and monoclonal antibodies are among the most promising biological approaches to cancer treatment which have so far been investigated. Both natural and recombinant interferon-alpha preparations have shown activity in a number of trials in hematologic malignancies, even in previously treated patients; activity in solid tumors, however, has been limited. Unconjugated monoclonal antibodies have been safely administered in several small trials and have had therapeutic value on occasion. In spite of a number of remaining problems and questions, monoclonal antibodies and their conjugates seem likely to find a number of distinct roles in cancer treatment; elimination of micrometastases and purging of bone marrow for grafting may be among these roles.Entities:
Mesh:
Substances:
Year: 1986 PMID: 3516264 DOI: 10.1007/bf01886730
Source DB: PubMed Journal: Breast Cancer Res Treat ISSN: 0167-6806 Impact factor: 4.872